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Abstract We report about a patient with infantile-onset
neurodegenerative disease associated with isolated mito-
chondrial respiratory chain complex III (cIII) deficiency.
The boy, now 13 years old, presented with language
regression and ataxia at 4 years of age and then showed a
progressive course resulting in the loss of autonomous gait
and speaking during the following 2 years. Brain MRI
disclosed bilateral striatal necrosis. Sequencing of a panel
containing nuclear genes associated with cIII deficiency
revealed a previously undescribed homozygous rearrange-
ment (c.782_786delinsGAAAAG) in TTC19 gene, which
results in a frameshift with premature termination (p.
Glu261Glyfs*8). TTC19 protein was absent in patient’s
fibroblasts.
TTC19 encodes tetratricopeptide 19, a putative assembly
factor for cIII. To date TTC19 mutations have been reported
only in few cases, invariably associated with cIII defi-
ciency, but presenting heterogeneous clinical phenotypes.
We reviewed the genetic, biochemical, clinical and
neuroradiological features of TTC19 mutant patients
described to date.
Introduction
Isolated deficiency of mitochondrial respiratory chain
(MRC) complex III (cIII) (MIM#124000) is a rare cause
of mitochondrial disorder. Excluding mutations in MTCYB,
the mitochondrial DNA (mtDNA) gene encoding cyto-
chrome b, mutations in nuclear genes encoding other
structural cIII subunits are extremely uncommon (Ghezzi
and Zeviani 2012; Miyake et al. 2013). Contrariwise,
several genetic defects have been described in cIII assembly
factor genes, including BCS1L (De Lonlay et al. 2001),
TTC19 (Ghezzi et al. 2011), and LYRM7 (Invernizzi et al.
2013). TTC19 mutations have been reported in few patients
with heterogeneous phenotypes ranging from early onset
neurodegenerative disorders (Ghezzi et al. 2011; Atwal
2013; Balasubramaniam et al. 2012) to adult forms with
psychiatric manifestations and cerebellar ataxia (Nogueira
et al. 2013; Morino et al. 2014). An overall evaluation of
known TTC19 mutant cases including genotype/phenotype
correlations has not been performed so far.
Bilateral striatal necrosis (BSN) includes a group of
syndromes, usually with onset in infancy, characterized by
bilateral and symmetrical degeneration of caudate and
putamen nuclei (neostriatum). BSN results from either
toxic exposure, infections and metabolic or neurodegenera-
tive disorders (Zevit et al. 2007), including some mitochon-
drial diseases.
We report a novel deleterious mutation in TTC19,
identified in a patient presenting with BSN and isolated
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mitochondrial cIII deficiency. In addition we report a
review of previously published TTC19 patients.
Case Report
Our proband is a boy, second child of healthy related (first
cousins) parents of Moroccan origin. Two younger sisters are
in good health; another sister died 1 week after birth for
unknown causes. He was born at term after uneventful
pregnancy; psychomotor development was normal, but delay
in language skills with possible deafness was referred. Since
the age of 4 years, he presented with walking impairment
and language regression that progressively worsened during
the following 2 years leading to loss of autonomous gait and
speaking. He was first examined at 9 years of age when he
established in Italy. He showed low body weight and height
(3rd percentile), diffuse muscle wasting, severe spastic
tetraparesis with marked dystonic postures involving both
upper and lower limbs and severe cognitive impairment. No
epilepsy was reported. Blood routine exams, including
copper and ceruloplasmin levels and urinary organic acids,
were normal. Elevated levels of lactate in plasma (4,269
umol/L; n.v. 580–2,100) and CSF (3,806 umol/L; n.v.
800–2,100) and of pyruvate in plasma (208 umol/L; n.v.
55–145) and CSF (180 umol/L; n.v. 45–135) were detected.
Fundus oculi, motor and sensory nerve conduction
velocities, and electroretinogram resulted normal. Visual
and brainstem auditory evoked potentials showed bilateral
increased latency and decreased amplitude. Electroenceph-
alography showed normal background activity and few
diffuse paroxysmal abnormalities during sleep. Brain MRI
showed bilateral hyperintensities of putamen and caudate
bodies (Fig. 1); no calcifications were present at CT.
Histological analysis of patient’s muscle biopsy showed
few hypotrophic fibers, with normal lipids and glycogen
content. An isolated cIII deficiency (50%) in muscle
homogenate was documented, whereas all MRC complex
activities were normal in fibroblasts.
Treatment with coenzymeQ10, thiamine, and riboflavin
was started, associated with symptomatic therapy with
baclofen. The patient is now 13 years old, and his clinical
condition appears stable.
Targeted resequencing of a panel containing nuclear genes
associated with cIII deficiency (BCS1L, TTC19, LYRM7,
UQCRB, UQCRQ) revealed the presence of a homozygous
variant in TTC19, a novel rearrangement (c.782_786delin-
sGAAAAG) resulting in a frameshift with a predicted
premature termination (p.Glu261Glyfs*8) (Fig. 2a, b). The
mutation was found to be heterozygous in both parents and
absent in two healthy siblings. Quantitative PCR revealed a
marked reduction of the TTC19 transcript in patient’s
fibroblasts (Fig. 2c), and Western blot analysis showed the
absence of TTC19 protein (Fig. 2d).
Discussion and Conclusion
Mutations in TTC19 have been rarely described in patients
with mitochondrial diseases. Eleven individuals, presenting
Fig. 1 Bilateral hyperintensities of the putamen and caudate bodies (more evident in left side) in coronal T2-weighted image (a), with a
cavitated appearance on transverse FLAIR sequence (b)
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with infantile or juvenile-adult onset, and eight different
TTC19 mutations have been reported so far (Table 1).
Ghezzi et al. first reported in 2011 the presence of
mutations in TTC19 in four Italian patients. Three of these
cases (P1–P3) carried a homozygous nucleotide change
(c.656T>C; p.Leu219*) predicting the synthesis of a
truncated protein and presented with infantile onset of
cognitive impairment and ataxia. Two patients (P2, P3)
showed a rapidly progressive course characterized by
severe cognitive regression, cerebellar and extrapyramidal
signs, hearing loss and severe axonal neuropathy. They
became bedridden, presented a fluctuating comatose state
requiring assisted ventilation and percutaneous endoscopic
gastrostomy. Brain MRI of P3 showed progressive necrotic
lesions in the brainstem and thalami and cerebellar atrophy.
P1, sister of P2 and carrying the same mutation, presented a
slowly progression of cerebellar and pyramidal signs and
developed axonal motor neuropathy, becoming wheelchair
bound since the age of 24 years. Brain MRI showed
multifocal involvement of the deep gray matter, severe
cerebellar atrophy and leukodystrophy. The fourth patient
(P4) carried another homozygous nonsense mutation
(c.517C>T; p.Gln173*). He presented with an adulthood
subacute onset and rapidly progressive multisystemic
neurological disease resulting in death 3 years later. Brain
MRI showed diffuse cortical atrophy and right caudate and
bilateral putamina involvement. Blood lactate was normal
in P1, increased in P3 and not investigated in the others. A
marked reduction of cIII activity in muscle homogenate
was revealed in all patients. Decreased TTC19 mRNA and
virtual absence of the protein in muscle tissue and/or
fibroblasts were also detected.
Nogueira et al. 2013 reported on a consanguineous family
with four affected siblings (P5–P8) carrying a novel mutation
(c.600_604delTGGC) predicting a frameshift and the synthe-
sis of a truncated TTC19 protein (p.Ala200Alafs*8).
(a) (b) 
(c) (d) 
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Fig. 2 (a) Snapshot from IGV software of the mutation identified in
the patient. A customized gene panel (TSCA, Illumina) was sequenced
using a MiSeq system. (b) Electropherograms of TTC19 gene showing
the homozygous rearrangement (c.782_786delinsGAAAAG) found in
the patient (pt) resulting in a frameshift with premature termination
(p.Glu261Glyfs*8); wild-type (wt) sequence in a control subject is also
shown. (c) Quantitative real-time PCR of TTC19 mRNA in control
(Ct) and patient’s (Pt) fibroblasts. (d) Immunoblot analysis of lysates
from control and patient’s fibroblasts using a-TTC19 and a-SDH70
antibodies
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The clinical phenotype was characterized by late onset
(ranging from adolescence to adulthood) with psychiatric
symptoms; subsequently patients displayed cerebellar signs
and mild pyramidal and extrapyramidal signs. In two siblings
(P5, P7) an axonal motor neuropathy was also present. Three
patients (P5–P7) showed a progressive course resulting in
death about 20 years after onset; the only alive patient (P8)
resulted stable 4 years after the disease onset. MRI showed a
severe olivopontocerebellar atrophy associated with necrosis
in the caudate, putamina and medullary olives. High lactate
levels are reported only in one patient (P5), while a marked
isolated cIII deficiency was documented in all muscle
samples.
An additional case (P9), compound heterozygous for the
c.600_603delTGGC and a novel nonsense mutation
(c.195G>A; p.Trp65*), was reported by Atwal. He
presented with psychomotor delay, followed by language
regression at 13 months, and subsequent stable clinical
course until the last observation (4 years of age). Brain MRI
disclosed necrosis in the putamina, caudate and brainstem.
Muscle biopsy showed decreased activity of MRC com-
plexes I + III, II, II + III and IV.
More recently, Morino at al. described a woman (P10)
with a spinocerebellar phenotype. She had an adulthood
onset with dysarthria at 31 years of age and rapidly
developed cognitive impairment, ataxia, and peripheral
signs (pes cavus) leading to loss of autonomous gait 3
years later. MRI showed involvement of inferior olives and
cerebellar atrophy. Lactate level was normal at onset, but
resulted elevated in subsequent measurements. Muscle
biopsy was not performed. Exome sequencing revealed a
novel homozygous nonsense mutation (c.829C>T; p.
Gln277*) in TTC19.
Finally, Balasubramaniam et al. reported the case of a
girl (P11) affected with a slowly progressive encephalomy-
opathy and MRI abnormalities in lentiform nuclei associ-
ated with a novel homozygous nonsense mutation
(c.574C>T; p.Gln192*). Plasma and CSF lactate levels
were reported normal.
Our patient (P12 in Table 1) is the fifth infantile case
associated with TTC19 mutation. The clinical onset and the
rapidly progressive course leading to spastic tetraparesis,
dystonic postures, and marked cognitive impairment were
similar to other infantile cases. Both our patient and
previous cases had no seizures. Axonal motor neuropathy,
described in some TTC19 mutant individuals, was not
present in P12.
The biochemical profile with marked cIII deficiency was
consistent in all reported cases, although in P9 reduction of
other MRC complex activities were found.
P12 brain MRI showed BSN. In 10/11 cases reported to
date, brain MRI was available; the most common alter-
ations were basal ganglia necrosis and subtentorial involve-
ment, including deep gray matter and cerebellar atrophy.
MRI alterations, always severe, were similar in infantile
and adult cases, in spite of a different clinical phenotype.
Our patient and P11 were the only cases without sub-
tentorial involvement.
BSN has been already reported as a typical MRI feature
in mitochondrial diseases caused by mutations in either
mitochondrial genes (ATP6, ND1, and ND6 encoding
subunits of respiratory chain complex V and I, respectively)
(Lal et al. 2013; Campos et al. 2013; Solano et al. 2003) or
in nuclear genes (NDUFV1 and NDUFS4 encoding
complex I subunits) (Lal et al. 2013; Budde et al. 2003);
AIFM1 encoding apoptosis-inducing factor, mitochondrial
1 (Ghezzi et al. 2010); and SLC25A19 encoding a
mitochondrial thiamine pyrophosphate transporter (Spiegel
et al. 2009). Thus, TTC19 must be added to the list of genes
associated with infantile mitochondrial disorders and
bilateral striatal necrosis.
Our report and the review of previous cases carrying
TTC19 mutations demonstrate that ataxia and impairment
of cortical functions leading to language or cognitive
regression are the clinical hallmarks of infantile-onset
forms, whereas psychiatric symptoms are typical of
juvenile-adult forms. Axonal motor neuropathy is frequent
but not always present. MRI pattern, characterized by both
supra- or subtentorial gray matter involvement and cerebel-
lar atrophy, shows some common features in spite of
different age of onset.
Decreased cIII activity was present in all patients
reported to date. Nevertheless, lactate levels may be normal
and lactic acidosis is not a reliable biomarker.
The review of published TTC19 mutant cases does not
suggest a strict and univocal genotype/phenotype correla-
tion, but underlines that TTC19-related diseases can be
severely disabling. Since almost all known TTC19 muta-
tions were associated with or are predicted to result in the
absence of the protein, the differences in disease severity
could not be easily ascribed to diverse deleterious effects of
different mutations. A larger set of TTC19 mutant patients
should be examined, and the use of unbiased approaches
for genetic analysis, such as targeted resequencing of broad
gene panel or exome sequencing, would allow to better
define the clinical spectrum of diseases caused by TTC19
mutations.
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Synopsis
We describe a novel deleterious mutation in TTC19
associated with early onset severe and progressive neuro-
logical deterioration. The review of previous cases does not
suggest a strict and univocal genotype/phenotype correla-
tion, but demonstrates that some clinical hallmarks and
common MRI pattern are available in spite of different age
of onset. Biochemical (decreased cIII activity) and molecu-
lar data (all known TTC19 mutations were associated with
or are predicted to result in the absence of the protein) are
common in spite of different phenotypes.
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